Osanni Bio Closes $190M Series B for Drug Discovery Platform

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Osanni Bio, a development-stage therapeutics platform based in San Francisco, California, has closed a $190 million Series B financing led by Patient Square Capital. Existing investors the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund also took part.

The company runs what it describes as an innovation engine built to discover new scientific insights, design novel drug concepts, and move programs efficiently toward proof-of-concept. It is currently advancing work in ophthalmology, cardiology, and other areas.

Proceeds from the financing will advance the company’s pipeline of multiple programs and scale its discovery and development process.

Osanni launched three years ago with a $27 million Series A. Founder and chief executive Michael Ackermann drew on his earlier experience founding Tarsus Pharmaceuticals, Oyster Point Pharma, Oculeve, and Presidio Medical when he started the company.

The raise marks a step into a more public, clinical phase for a company that has operated quietly, and reflects continued investor confidence in platform-based approaches to drug discovery.